Biogen Idec Inc (BIIB) 315.44 $BIIB
FDA Drug Approvals, Dividends, Fast Track Designation, Event Sponsorship, and Expansion of Role - Analyst Notes on Biogen Idec, UnitedHealth Group, GW Pharmaceuticals, Questcor and Cigna
PR Newswire - 20 mins ago
Today, Analysts Review released its analysts' notes regarding Biogen Idec Inc. (NASDAQ: BIIB), UnitedHealth Group Inc. (NYSE: UNH), GW Pharmaceuticals PLC (NASDAQ: GWPH), Questcor Pharmaceuticals Inc. (NASDAQ: QCOR) and Cigna Corporation (NYSE: CI). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/3590-100free.
RBCC to Expand Market for 'Underused' Addiction Treatment With New Technology
Business Wire - 30 mins ago
Rainbow Coral Corp. (OTCBB: RBCC) received a boost recently when researchers reported that a medication that could help tens of thousands of alcoholics quit drinking are underused.
Why the Future Is Bright for Isis Pharmaceuticals
Todd Campbell, The Motley Fool - Motley Fool - Tue Jun 10, 5:30PM CDT
Isis Pharmaceuticals shares have surged this past week on news that it has received two milestone payments for advancing new drugs into phase 1 trials. Those milestone payments from Biogen and AstraZeneca successfully shifted attention away...
Up 37%: Can Receptos Compete With Novartis?
Michael Douglass and David Williamson, The Motley Fool - Motley Fool - Tue Jun 10, 5:15PM CDT
Receptos shareholders had a great day today, with the stock up 37% on exciting phase 2 data for its lead drug candidate RPC1063 in multiple sclerosis. And with a phase 3 trial pitting RPC1063 against Biogen Idec 's Avonex ongoing, there is some...
Can Receptos' New Drug Beat Biogen?
Todd Campbell, The Motley Fool - Motley Fool - Tue Jun 10, 1:30PM CDT
Receptos shares surged by a 36% this morning following news that the company's RPC1063 met its primary endpoint as a treatment for relapsing multiple sclerosis. The midstage trial results offer investors hope that Receptos' product will...
Isis Pharma Earns Milestone Payment on Study Initiation - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jun 10, 10:30AM CDT
Isis Pharmaceuticals, Inc. (ISIS) earned a milestone payment of $14 million from Biogen with the initiation of a phase I study on ISIS-DMPKRx for the treatment of myotonic dystrophy type I (DM1).
The Pulmonary Fibrosis Foundation Receives Grant From Biogen Idec To Support The PFF Patient Registry
PR Newswire - Tue Jun 10, 10:00AM CDT
The Pulmonary Fibrosis Foundation (PFF) today announced a key partnership with Biogen Idec in support of the PFF Patient Registry. The PFF announced its plan to establish a PFF Patient Registry, along with a PFF Care Center Network (CCN), at its biennial PFF Summit held in December 2013.
Lupus Nephritis - Pipeline Review, H1 2014
M2 - Tue Jun 10, 3:41AM CDT
Research and Markets (http://www.researchandmarkets.com/research/fdzqtl/lupus_nephritis) has announced the addition of the "Lupus Nephritis - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Lupus Nephritis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Lupus Nephritis and special features on late-stage and discontinued projects. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Companies Mentioned: - Bristol-Myers Squibb Company - Baxter International Inc. - Johnson & Johnson - Biogen Idec Inc. - GlaxoSmithKline plc - Takeda Pharmaceutical Company Limited - Teva Pharmaceutical Industries Limited - Noxxon Pharma AG - Anthera Pharmaceuticals Inc. - Kadmon Pharmaceuticals, LLC - Azano Pharmaceuticals Inc. For more information visit http://www.researchandmarkets.com/research/fd..._nephritis
Biogen's Eloctate Approved in the U.S. - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jun 09, 12:50PM CDT
The FDA approved Biogen's (BIIB) hemophilia A treatment, Eloctate, which will be launched in July.
By End of 2018 the Global Protein Therapeutics Market is Estimated to Reach US$ 165 Billion as New Products Enter the Sector
M2 - Mon Jun 09, 9:56AM CDT
Research and Markets (http://www.researchandmarkets.com/research/c3s8lj/global_protein) has announced the addition of the "Global Protein Therapeutics Market Outlook 2018" report to their offering. According to this new research report, Global Protein Therapeutics Market Outlook 2018, a large number of market players has been developing monoclonal antibodies (mAbs). This research has found that mAbs contribute the largest shares in the number of protein therapeutic products under pipeline. The report, in this context, gives a comprehensive analysis of the current and future patterns of revenue generation with respect to mAbs and other segments. The report takes into account all the key aspects of the worldwide protein therapeutics market and projects the market during the period 2012-2018. It prudently analyzes all the industry segments in an effective manner by focusing on major players and products, recent developments, application support in terms of indications, geographical performances and last but not the least, current and future market sizes. Moreover, the report provides a summary of the recent trends that may have an impact on the future industry performance. Companies Mentioned: - Abbott Laboratories - Amgen Inc. - Biogen Idec Inc. - Eli Lilly & Company - Johnson & Johnson - Merck Serono S.A. - Novo Nordisk - Pfizer - Roche Group - Sanofi-Aventis For more information visit http://www.researchandmarkets.com/research/c3...al_protein About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Stock Indexes Slightly Up; Apple Split Takes Effect
at Investor's Business Daily - Mon Jun 09, 9:27AM CDT
Stocks hovered modestly above the break-even line in early trading Monday. The Nasdaq, S&P 500 and Dow Jones industrial average were up 0.1% each. Volume in the stock market today was running higher on the Nasdaq and lower on the NYSE vs. Friday's...
Isis Pharmaceuticals Initiates Phase 1 Study of ISIS-DMPK Rx to Treat Myotonic Dystrophy Type 1
PR Newswire - Mon Jun 09, 6:00AM CDT
Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it has initiated a Phase 1 study for ISIS-DMPKRx. Isis earned a $14 million milestone payment from Biogen Idec associated with this achievement. ISIS-DMPKRx is designed to reduce the production of toxic dystrophia myotonica-protein kinase (DMPK) RNA in cells, including muscle cells, for the treatment of Myotonic Dystrophy Type 1 (DM1).
Global Protein Therapeutics Market 2012-2016: CAGR, Market Size, Forecasts till 2016
M2 - Mon Jun 09, 4:39AM CDT
Research and Markets (http://www.researchandmarkets.com/research/gvn6gl/global_protein) has announced the addition of the "Global Protein Therapeutics Market 2012-2016" report to their offering. The analysts forecast the Global Protein Therapeutics market to grow at a CAGR of 7.08 percent over the period 2012-2016. One of the key factors contributing to this market growth is the increasing prevalence of chronic diseases. The market has also been witnessing increasing outsourcing of drug development. However, patent-expiration of top-selling drugs could pose a challenge to the growth of this market. The key vendors dominating this space include Roche Holding Ltd., Amgen Inc., Abbott Laboratories, J&J, and Novo Nordisk A/S. The other vendors mentioned in this report are AstraZeneca plc, Biogen Idec Inc., Eli Lilly and Co., Novartis International AG, Bristol Myers Squibb Co., Merck and Co. Inc., Pfizer Inc., Curis Inc., UCB S.A., Elan Corporations Plc, Human Genome Sciences Inc., Daiichi Sankyo Co. Ltd., and GlaxoSmithKline plc. Commenting on the report, an analyst from the Healthcare team said: The development and manufacture of drugs is a complex and time-consuming process, and also requires huge financial investments. As many vendors in the market are facing the problem of declining venture capital investments, they are increasingly following the strategy of outsourcing. Many vendors outsource different parts of the R&D process such as product characterization testing and toxicology testing to CROs. Likewise, a few vendors are increasingly outsourcing a part of their manufacturing process, or the entire manufacturing process to various organizations. Thus, the Global Protein Therapeutics market is currently witnessing the trend of increased outsourcing of drug development activities. For more information visit http://www.researchandmarkets.com/research/gv...al_protein About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Chronic Lymphocytic Leukaemia (CLL) Therapeutics Market Investigated by FirstWord in In-demand Report Published at MarketPublishers.com
PRWeb - Mon Jun 09, 3:34AM CDT
Chronic lymphocytic leukaemia (CLL) is the most common type of the leukaemias. Nevertheless, until recently, it has been underserved in terms of effective therapeutic options. However, a revolution in targeted and personalized therapies is tremendously altering the treatment algorithm and also spurs the development of the CLL therapeutic market. The list of the marketed CLL drugs includes Rituxan/MabThera, Arzerra, Gazyva, Campath/MabCampath and Imbruvica. Meanwhile, pipeline drugs include idelalisib, ABT-199, IPI-145, Revlimid, and alvocidib.
The US Food and Drug Administration (FDA) approves Eloctate(TM)
Thomson Reuters ONE - Mon Jun 09, 1:02AM CDT
Swedish Orphan Biovitrum AB (publ) (Sobi) partner Biogen Idechas announced that the US Food and Drug Administration (FDA) has approved Eloctate [Antihaemophilic Factor VIII (Recombinant), Fc Fusion Protein] for the control and prevention of bleeding episodes, perioperative (surgical) management and routine prophylaxis in adults and children with haemophilia A.This is the first regulatory approval worldwide for Eloctate and the therapy is currently under review by regulatory authorities in several other countries including Canada, Australia and Japan.
This Week in Biotech: A Trifecta of Disappointment Mars ASCO While Biogen Scores a Big Victory
Sean Williams, The Motley Fool - Motley Fool - Sat Jun 07, 12:05PM CDT
With the SPDR S&P Biotech Index up 25% over the trailing 12-month period , it's evident that investment dollars are willingly flowing into the biotech sector. Keeping that in mind, let's have a look at some of the rulings, studies, and...
3 Spectacular Ways Samsung Could Disrupt the Health Care Industry
Leo Sun, The Motley Fool - Motley Fool - Sat Jun 07, 10:05AM CDT
When most investors think of Samsung , they inevitably think of smartphones, tablets, and TVs. Yet over the past several years, Samsung has also beefed up its presence in the health care industry through investments in medical devices,...
FDA clears Biogen Idec's hemophilia A drug
AP - Fri Jun 06, 5:25PM CDT
NEW YORK (AP) — U.S. regulators on Friday approved Biogen Idec's drug Eloctate, a hemophilia A treatment that is designed to last longer than older drugs.
FDA Approves Biogen Idec's ELOCTATE(TM), First Hemophilia A Therapy to Extend the Interval between Prophylactic Infusions, for Both Adults and Children
Business Wire - Fri Jun 06, 3:55PM CDT
--- Approval of Biogen Idec's Second Innovative Hemophilia Therapy with Prolonged Circulation This Year -
FDA Drug Approvals, Dividends, Fast Track Designation, Event Sponsorship, and Expansion of Role - Analyst Notes on Biogen Idec, UnitedHealth Group, GW Pharmaceuticals, Questcor and Cigna
PR Newswire - 20 mins ago
Today, Analysts Review released its analysts' notes regarding Biogen Idec Inc. (NASDAQ: BIIB), UnitedHealth Group Inc. (NYSE: UNH), GW Pharmaceuticals PLC (NASDAQ: GWPH), Questcor Pharmaceuticals Inc. (NASDAQ: QCOR) and Cigna Corporation (NYSE: CI). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/3590-100free.
RBCC to Expand Market for 'Underused' Addiction Treatment With New Technology
Business Wire - 30 mins ago
Rainbow Coral Corp. (OTCBB: RBCC) received a boost recently when researchers reported that a medication that could help tens of thousands of alcoholics quit drinking are underused.
Why the Future Is Bright for Isis Pharmaceuticals
Todd Campbell, The Motley Fool - Motley Fool - Tue Jun 10, 5:30PM CDT
Isis Pharmaceuticals shares have surged this past week on news that it has received two milestone payments for advancing new drugs into phase 1 trials. Those milestone payments from Biogen and AstraZeneca successfully shifted attention away...
Up 37%: Can Receptos Compete With Novartis?
Michael Douglass and David Williamson, The Motley Fool - Motley Fool - Tue Jun 10, 5:15PM CDT
Receptos shareholders had a great day today, with the stock up 37% on exciting phase 2 data for its lead drug candidate RPC1063 in multiple sclerosis. And with a phase 3 trial pitting RPC1063 against Biogen Idec 's Avonex ongoing, there is some...
Can Receptos' New Drug Beat Biogen?
Todd Campbell, The Motley Fool - Motley Fool - Tue Jun 10, 1:30PM CDT
Receptos shares surged by a 36% this morning following news that the company's RPC1063 met its primary endpoint as a treatment for relapsing multiple sclerosis. The midstage trial results offer investors hope that Receptos' product will...
Isis Pharma Earns Milestone Payment on Study Initiation - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jun 10, 10:30AM CDT
Isis Pharmaceuticals, Inc. (ISIS) earned a milestone payment of $14 million from Biogen with the initiation of a phase I study on ISIS-DMPKRx for the treatment of myotonic dystrophy type I (DM1).
The Pulmonary Fibrosis Foundation Receives Grant From Biogen Idec To Support The PFF Patient Registry
PR Newswire - Tue Jun 10, 10:00AM CDT
The Pulmonary Fibrosis Foundation (PFF) today announced a key partnership with Biogen Idec in support of the PFF Patient Registry. The PFF announced its plan to establish a PFF Patient Registry, along with a PFF Care Center Network (CCN), at its biennial PFF Summit held in December 2013.
Lupus Nephritis - Pipeline Review, H1 2014
M2 - Tue Jun 10, 3:41AM CDT
Research and Markets (http://www.researchandmarkets.com/research/fdzqtl/lupus_nephritis) has announced the addition of the "Lupus Nephritis - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Lupus Nephritis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Lupus Nephritis and special features on late-stage and discontinued projects. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Companies Mentioned: - Bristol-Myers Squibb Company - Baxter International Inc. - Johnson & Johnson - Biogen Idec Inc. - GlaxoSmithKline plc - Takeda Pharmaceutical Company Limited - Teva Pharmaceutical Industries Limited - Noxxon Pharma AG - Anthera Pharmaceuticals Inc. - Kadmon Pharmaceuticals, LLC - Azano Pharmaceuticals Inc. For more information visit http://www.researchandmarkets.com/research/fd..._nephritis
Biogen's Eloctate Approved in the U.S. - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jun 09, 12:50PM CDT
The FDA approved Biogen's (BIIB) hemophilia A treatment, Eloctate, which will be launched in July.
By End of 2018 the Global Protein Therapeutics Market is Estimated to Reach US$ 165 Billion as New Products Enter the Sector
M2 - Mon Jun 09, 9:56AM CDT
Research and Markets (http://www.researchandmarkets.com/research/c3s8lj/global_protein) has announced the addition of the "Global Protein Therapeutics Market Outlook 2018" report to their offering. According to this new research report, Global Protein Therapeutics Market Outlook 2018, a large number of market players has been developing monoclonal antibodies (mAbs). This research has found that mAbs contribute the largest shares in the number of protein therapeutic products under pipeline. The report, in this context, gives a comprehensive analysis of the current and future patterns of revenue generation with respect to mAbs and other segments. The report takes into account all the key aspects of the worldwide protein therapeutics market and projects the market during the period 2012-2018. It prudently analyzes all the industry segments in an effective manner by focusing on major players and products, recent developments, application support in terms of indications, geographical performances and last but not the least, current and future market sizes. Moreover, the report provides a summary of the recent trends that may have an impact on the future industry performance. Companies Mentioned: - Abbott Laboratories - Amgen Inc. - Biogen Idec Inc. - Eli Lilly & Company - Johnson & Johnson - Merck Serono S.A. - Novo Nordisk - Pfizer - Roche Group - Sanofi-Aventis For more information visit http://www.researchandmarkets.com/research/c3...al_protein About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Stock Indexes Slightly Up; Apple Split Takes Effect
at Investor's Business Daily - Mon Jun 09, 9:27AM CDT
Stocks hovered modestly above the break-even line in early trading Monday. The Nasdaq, S&P 500 and Dow Jones industrial average were up 0.1% each. Volume in the stock market today was running higher on the Nasdaq and lower on the NYSE vs. Friday's...
Isis Pharmaceuticals Initiates Phase 1 Study of ISIS-DMPK Rx to Treat Myotonic Dystrophy Type 1
PR Newswire - Mon Jun 09, 6:00AM CDT
Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it has initiated a Phase 1 study for ISIS-DMPKRx. Isis earned a $14 million milestone payment from Biogen Idec associated with this achievement. ISIS-DMPKRx is designed to reduce the production of toxic dystrophia myotonica-protein kinase (DMPK) RNA in cells, including muscle cells, for the treatment of Myotonic Dystrophy Type 1 (DM1).
Global Protein Therapeutics Market 2012-2016: CAGR, Market Size, Forecasts till 2016
M2 - Mon Jun 09, 4:39AM CDT
Research and Markets (http://www.researchandmarkets.com/research/gvn6gl/global_protein) has announced the addition of the "Global Protein Therapeutics Market 2012-2016" report to their offering. The analysts forecast the Global Protein Therapeutics market to grow at a CAGR of 7.08 percent over the period 2012-2016. One of the key factors contributing to this market growth is the increasing prevalence of chronic diseases. The market has also been witnessing increasing outsourcing of drug development. However, patent-expiration of top-selling drugs could pose a challenge to the growth of this market. The key vendors dominating this space include Roche Holding Ltd., Amgen Inc., Abbott Laboratories, J&J, and Novo Nordisk A/S. The other vendors mentioned in this report are AstraZeneca plc, Biogen Idec Inc., Eli Lilly and Co., Novartis International AG, Bristol Myers Squibb Co., Merck and Co. Inc., Pfizer Inc., Curis Inc., UCB S.A., Elan Corporations Plc, Human Genome Sciences Inc., Daiichi Sankyo Co. Ltd., and GlaxoSmithKline plc. Commenting on the report, an analyst from the Healthcare team said: The development and manufacture of drugs is a complex and time-consuming process, and also requires huge financial investments. As many vendors in the market are facing the problem of declining venture capital investments, they are increasingly following the strategy of outsourcing. Many vendors outsource different parts of the R&D process such as product characterization testing and toxicology testing to CROs. Likewise, a few vendors are increasingly outsourcing a part of their manufacturing process, or the entire manufacturing process to various organizations. Thus, the Global Protein Therapeutics market is currently witnessing the trend of increased outsourcing of drug development activities. For more information visit http://www.researchandmarkets.com/research/gv...al_protein About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Chronic Lymphocytic Leukaemia (CLL) Therapeutics Market Investigated by FirstWord in In-demand Report Published at MarketPublishers.com
PRWeb - Mon Jun 09, 3:34AM CDT
Chronic lymphocytic leukaemia (CLL) is the most common type of the leukaemias. Nevertheless, until recently, it has been underserved in terms of effective therapeutic options. However, a revolution in targeted and personalized therapies is tremendously altering the treatment algorithm and also spurs the development of the CLL therapeutic market. The list of the marketed CLL drugs includes Rituxan/MabThera, Arzerra, Gazyva, Campath/MabCampath and Imbruvica. Meanwhile, pipeline drugs include idelalisib, ABT-199, IPI-145, Revlimid, and alvocidib.
The US Food and Drug Administration (FDA) approves Eloctate(TM)
Thomson Reuters ONE - Mon Jun 09, 1:02AM CDT
Swedish Orphan Biovitrum AB (publ) (Sobi) partner Biogen Idechas announced that the US Food and Drug Administration (FDA) has approved Eloctate [Antihaemophilic Factor VIII (Recombinant), Fc Fusion Protein] for the control and prevention of bleeding episodes, perioperative (surgical) management and routine prophylaxis in adults and children with haemophilia A.This is the first regulatory approval worldwide for Eloctate and the therapy is currently under review by regulatory authorities in several other countries including Canada, Australia and Japan.
This Week in Biotech: A Trifecta of Disappointment Mars ASCO While Biogen Scores a Big Victory
Sean Williams, The Motley Fool - Motley Fool - Sat Jun 07, 12:05PM CDT
With the SPDR S&P Biotech Index up 25% over the trailing 12-month period , it's evident that investment dollars are willingly flowing into the biotech sector. Keeping that in mind, let's have a look at some of the rulings, studies, and...
3 Spectacular Ways Samsung Could Disrupt the Health Care Industry
Leo Sun, The Motley Fool - Motley Fool - Sat Jun 07, 10:05AM CDT
When most investors think of Samsung , they inevitably think of smartphones, tablets, and TVs. Yet over the past several years, Samsung has also beefed up its presence in the health care industry through investments in medical devices,...
FDA clears Biogen Idec's hemophilia A drug
AP - Fri Jun 06, 5:25PM CDT
NEW YORK (AP) — U.S. regulators on Friday approved Biogen Idec's drug Eloctate, a hemophilia A treatment that is designed to last longer than older drugs.
FDA Approves Biogen Idec's ELOCTATE(TM), First Hemophilia A Therapy to Extend the Interval between Prophylactic Infusions, for Both Adults and Children
Business Wire - Fri Jun 06, 3:55PM CDT
--- Approval of Biogen Idec's Second Innovative Hemophilia Therapy with Prolonged Circulation This Year -
